Find-Health-Articles.com - making medical research available to everyone

Models, Economic (Latest Articles)

 

Latest indexed articles for 'Models, Economic'

Articles 1 to 10 of 200:

Medicine as ecoculture.

18 Oct 2009 The use of diagnostic tests, especially imaging studies, varies markedly across the United States-with higher costs but no better patient outcomes associated with the highest-use regions. A proposed new model of the health care system draws on an ...
rec_pub_19841458-medicine-ecoculture.htm


A revealed preference approach to estimating supply curves for ecosystem services: use of auctions to set payments for soil erosion control in Indonesia.

18 Oct 2009 To supply ecosystem services, private landholders incur costs. Knowledge of these costs is critical for the design of conservation-payment programs. Estimating these costs accurately is difficult because the minimum acceptable payment to a potential ...
rec_pub_18983597-a-revealed-preference-approach-estimating-supply-curves-ecosystem.htm


Ecological and economic analysis of poaching of the greater one-horned rhinoceros (Rhinoceros unicornis) in Nepal.

29 Sep 2009 Nepal's greater one-horned rhinoceros (Rhinoceros unicornis) faces serious threats from poaching. Poaching of these rhinos is a complex problem, influenced by such diverse factors as the price of rhino horn on the international market, local ...
rec_pub_19831064-ecological-economic-analysis-poaching-greater-horned-rhinoceros.htm


Cost effectiveness of enoxaparin in acute ST-segment elevation myocardial infarction: the ExTRACT-TIMI 25 (Enoxaparin and Thrombolysis Reperfusion for Acute Myocardial Infarction Treatment-Thrombolysis In Myocardial Infarction 25) study.

27 Sep 2009 OBJECTIVES: We used a U.S. model of health care costs to examine the cost effectiveness of enoxaparin compared with unfractionated heparin (UFH) as adjunctive therapy for fibrinolysis in patients with ST-segment elevation myocardial infarction ...
rec_pub_19778669-cost-effectiveness-enoxaparin-acute-st-segment-elevation-myocardial.htm


The benefits of risk factor prevention in Americans aged 51 years and older.

15 Sep 2009 OBJECTIVES: We assessed the potential health and economic benefits of reducing common risk factors in older Americans. METHODS: A dynamic simulation model tracked a national cohort of persons 51 and 52 years of age to project their health and ...
rec_pub_19762651-the-benefits-risk-factor-prevention-americans-aged-51-years-older.htm


Early-warning signals for critical transitions.

Sep 2009 Complex dynamical systems, ranging from ecosystems to financial markets and the climate, can have tipping points at which a sudden shift to a contrasting dynamical regime may occur. Although predicting such critical points before they are reached is ...
rec_pub_19727193-early-warning-signals-critical-transitions.htm


Comparing the cost-effectiveness of disease-modifying drugs for the first-line treatment of relapsing-remitting multiple sclerosis.

30 Aug 2009 BACKGROUND: Multiple sclerosis (MS) is an inflammatory autoimmune disorder of the central nervous system that primarily afflicts young adults. Approximately 400,000 people in the United States are affected by MS. Although several forms of MS exist, ...
rec_pub_19739877-comparing-cost-effectiveness-disease-modifying-drugs-line-treatment.htm


Coevolution of adaptive technology, maladaptive culture and population size in a producer-scrounger game.

17 Aug 2009 Technology (i.e. tools, methods of cultivation and domestication, systems of construction and appropriation, machines) has increased the vital rates of humans, and is one of the defining features of the transition from Malthusian ecological ...
rec_pub_19692409-coevolution-adaptive-technology-maladaptive-culture-population-size.htm


Saving for an uncertain future.

10 Aug 2009
rec_pub_19706495-saving-uncertain-future.htm


Economic evaluation of human papillomavirus vaccination in developed countries.

9 Aug 2009 BACKGROUND: With promising efficacy results from randomized control trials of human papillomavirus (HPV) vaccines and the availability of new screening paradigms, policymakers are being asked to make recommendations and decisions regarding the ...
rec_pub_19684446-economic-evaluation-human-papillomavirus-vaccination-developed.htm

Results: [1-10] [11-20] [21-30] [31-40] [41-50] [51-60] [61-70] [71-80] [81-90] [91-100] [101-110] [111-120] [121-130] [131-140] [141-150] [151-160] [161-170] [171-180] [181-190] [191-200]

© Advanogy LLC 2003-2010 - All rights reserved. Terms of Use | Contact Us | Index